Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 17, 2007 - Issue 8
Submit an article Journal homepage
93
Views
2
CrossRef citations to date
0
Altmetric
Patenting Perspective

Patents on therapeutics in developing countries: the challenges ahead

Ashish Bhalla Post Graduate Institute of Medical Education and Research, Department of Internal Medicine, Chandigarh, 160012, India +91 9417023973; +91 9914299536; [email protected]; [email protected]
,
Vikas Suri Post Graduate Institute of Medical Education and Research, Department of Internal Medicine, Chandigarh, 160012, India +91 9417023973; +91 9914299536; [email protected]; [email protected]
&
Samir Malhotra Post Graduate Institute of Medical Education and Research, Department of Clinical Pharmacology, Chandigarh, 160012, India
Pages 1015-1025 | Published online: 16 Aug 2007

Bibliography

  • Infectious diseases are the biggest killer of the young: WHO Report (1999).
  • WESTOFF C, ROSENFIELD A: PRC executive summary: the globalization of infectious disease. Population Resource Centre (2004) [Available on net].
  • Changing history: The World Health Report (2004).
  • Top ten causes of death: WHO fact sheet No. 310. WHO February (2007).
  • MATHERS CD, LONCAR D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. (2006) 3(11):E442.
  • REPLOGLE J: Central American trade pact may limit access to generics. Lancet (2004) 363:1612-1613.
  • TROUILLER P, OLLIARO P, TORREELE E et al.: Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet (2002) 359:2188-2194.
  • ZACHER MW: Global epidemiological surveillance: international cooperation to monitor infectious diseases. In: Global Public Goods: International Cooperation in the 21st Century. Kaul I, Grunberg I, Stern M (Eds), New York: Oxford University Press (1999):266-283.
  • IMS Health IMS reports constant dollar growth in 2002 audited global pharmaceutical sales to $400.6 billion (2003) cited by Dentico N, Ford. N. The courage to change the rules: a proposal for an essential health R&D treaty. PLoS Med. (2005) 2(2):E14.
  • HOLLIS A: An efficient reward system for pharmaceutical innovation (2004) cited by Dentico N, Ford N. The courage to change the rules: a proposal for an essential health R&D treaty. PLoS Med. (2005) 2(2):E14.
  • LYBECKER C: Rx roulette: counterfeit pharmaceuticals in developing nations (2003) cited by Dentico N, Ford N. The courage to change the rules: a proposal for an essential health R&D treaty. PLoS Med. (2005) 2(2):E14.
  • MAHAN D: Profiting from pain: where prescription drug dollars go (2002) cited by Dentico N, Ford N. The courage to change the rules: a proposal for an essential health R&D treaty. PLoS Med. (2005) 2(2):E14.
  • [Anonymous]. (13 November 2004) The cost of ideas. Economist 85. cited by Dentico N, Ford N. The courage to change the rules: a proposal for an essential health R&D treaty. PLoS Med. (2005) 2(2):E14.
  • GILBERT J, HENSKE P, SINGH A: Rebuilding big pharma's business model. In vivo: the Business and Medicine Report (2003) 21:73.
  • Prophylactic and therapeutics substances. In: Twenty-Eighth World Health Assembly, 13 – 30 May 1975, Geneva, Switzerland. Part 1: resolutions and decisions, annexes. World Health Organization: Geneva (Official Records of the World Health Organization, No. 226, annex 13) (1975):96-110.
  • JALLOW MT, LUNDE PK: Drugs in developing countries. Current status, problems and possible solutions [in Norwegian]. Tidsskr Nor Laegeforen (1991) 111:1960-1967.
  • The selection of essential drugs: report of a WHO expert committee. World Health Organ. Tech. Rep. Ser. (1977) 615:1-36.
  • World Health Organization. The world drug situation. World Health Organization, Geneva (1988):53.
  • REIDENBERG MM: Essential drugs and WHO model list: addressing new issues. Report of a workshop focusing on the report of the World Health Organization Expert Committee on the Use of Essential Drugs. Clin. Pharmacol. Ther. (1996) 59:251-257.
  • HOGERZEIL HV: IDA and the concept of essential drugs. Int. J. Risk Saf. Med. (1999) 12:75-77.
  • OLWENY C: Bioethics in developing countries: ethics of scarcity and sacrifice. J. Med. Ethics (1994) 20:169-174.
  • SIKORA K, ADVANI S, KOROLTCHOUK V et al.: Essential drugs for cancer therapy: a World Health Organization consultation. Ann. Oncol. (1999) 10:385-390.
  • HEYMANN DL: (Executive director, communicable disease program, WHO) Neglected infectious disease: the power of unconventional approaches.
  • HOGERZEIL HV, BIMO ROSS-DEGNAN D, LAING RO et al.: Field tests for rational drug use in twelve developing countries. Lancet (1993) 342:1408-1410.
  • DE VRIES TPGM, HENNING RH, HOGERZEIL HV et al.: Import of a short course in pharmacotherapy for undergraduate medical students: an international randomised controlled study. Lancet (1995) 346:1454-1457.
  • World Health Organization (1997, 1999). Quality Assurance of Pharmaceuticals. Volume 1 and 2. World Health Organization: Geneva.
  • STEINBROOK R: Tuberculosis and HIV in India. NEJM (2007) 356:1198-1199.
  • HORTON R: WHO: the casualties and compromises of renewal. Lancet (2002) 359:1605-1611.
  • HORTON R: WHO's mandate: a damaging reinterpretation is taking place. Lancet (2002) 360:960-961.
  • PECOUL B, CHIRAC P, TROUELLER P, PINEL J: Access to essential drugs in poor countries. JAMA (1999) 281:361-367.
  • DI MASI J, SEIBRING MA, LASAGNA L: New drug developments in the United States from 1963 to 1992. Clin. Pharmacol. Ther. (1994) 55:609-622.
  • GRABOWSKI H: The effect of pharmacoeconomics on company research and development decisions. Pharmacoeconomics (1997) 5:389-397.
  • GRABOWSKI H, VERNON JM: Returns to R&D on new drug introduction in the 1980s. J. Health Economics (1994) 13:383-406.
  • SYKES R: The contribution of the research-based pharmaceutical industry. World Health Organization and International Federation of Pharmaceutical Manufacturers Association roundtable. Proceedings, 21 October 1998; WHO.
  • VELASQUEZ G, BOULET P: Essential drugs in the new international economic environment. Bull. World Health Org. (1999) 77:288-292.
  • FASEHUN F: The antibacterial paradox: essential drugs, effectiveness, and cost. Bull. World Health Org. (1999) 77:211-216.
  • REICH MR: The global drug gap. Science (2000) 287:1979-1981.
  • Public Law United States Federal Food, Drug and Cosmetic Act – Orphan Drug Act. PL 97-414. (4 January 1983).
  • WOLF A, LES ORPHELINS DE LA SANTé: European Union (1998) Proposition de Règlement (CE) du Parlement européen et du Conseil concernant les médicaments orphelins INSERM (1994):26.
  • TROUILLER C, BATTISTELLA J, PINEL B, PECOUL: Is orphan drug status beneficial to tropical disease control? Comparison of the Ameican and future European orphan drug acts. Trop. Med. Intern. Health (1999) 4:412-420.
  • OLLIARO P: Will the fight against tropical diseases benefit from orphan drug status? Trop. Med. Intern. Health (1997) 2:113-115.
  • Anonymous: Buying into the orphan drug market. Lancet (1995) 346:917.
  • National Institute for Health Care Management Research and Educational Foundation. Changing patterns of pharmaceutical innovation (2002).
  • KREMER M: A purchasing commitment for new vaccines. Part II: design issues. In: Innovation Policy and the Economy. Jaffe A, Lerner J, Stern S (Eds), Boston: Massachusetts. Inst. Technol. (2001):73-118.
  • SACHS J: Helping the world's poorest. Economist (1999) 52:11-12.
  • GANSLANDT M, MASKUS K, WONG E: Developing and distributing essential medicines to poor countries: the DEFEND proposal. The World Economy (2001) 24:779-795.
  • PéCOUL B: From pipeline to patients: developing new drugs for neglected diseases. PLoS Med. (2004) 1:E6.
  • NWAKA S, RIDLEY R: Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat. Rev. Drug Discov. (2003) 2:919.
  • MAURER SM, RAI A, SALI A: Finding cures for tropical diseases: is open source an answer? PLoS Med. (2004) 1(3):E56.
  • SMITH J: Patenting the sun: polio and the Salk vaccine. New York: Anchor/Doubleday (199)1:416.
  • The Cambia BIOS initiative: biological innovation for open society cited by Dentico N, Ford N. The courage to change the rules: a proposal for an essential health R&D treaty. PLoS Med. (2005) 2(2):E14.
  • DENTICO N, FORD N: The courage to change the rules: a proposal for an essential health R&D treaty. PLoS Med. (2005) 2:E14.
  • BARBOUR V, COHEN B, YAMEY G: A new vision for clinical trials in Africa. PLoS Med. (2004) 1:E71.
  • MOSES H, MARTIN JB: Academic relationships with industry: a new model for biomedical research. JAMA (2001) 285:933-935.
  • YACH D, HAWKES C, GOULD CL, HOFMAN KJ: The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA (2004) 291:2616-2622.
  • GANSLANDT M, MASKUS K, WONG E: Developing and distributing essential medicines to poor countries: the DEFEND proposal. The World Economy (2001) 24:779-795.
  • Participants in the 2001 conference on ethical aspects of research in the developing countries. Science (2002) 298:2133-2134.
  • NUNDY S, GULATI CM: A new colonialism? Conducting clinical trials in India. NEJM (2005) 352:1633-1636.

Websites

  • http://www.globalhealth.org/view_top.php3?id=228 Infectious diseases: Global Health council (2007).
  • http://www.wto.org/ World Trade Organization: declaration on the TRIPS agreement and public health. Adopted on 14 November 2001.
  • http://www.who.int/en/ WHO model formulary (MF).
  • http://www.who.int/medicines/publications/monitor/en/index.html WHO essential drugs monitor.
  • http://www.fao.org/AG/cgrfa/itpgr.htm The international treaty on plant genetic resources for food and agriculture.
  • http://www.sciam.com/article.cfm?articleID=00033282-DBF5-10F9-975883414B7F0000&sc=I100322 SINHA G: Out sourcing drug work. Scientific American online 2004.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.